Conflicting data exist regarding the effect of efavirenz (EFV) plasma concentrations on central nervous system (CNS) toxicity. We aimed to determine whether patients with high EFV plasma concentrations have an increased likelihood of toxicity-driven EFV discontinuations.
Methods
EFV plasma concentrations were measured from patients in the EuroSIDA study starting EFV after 1 January 1999. Patients with a plasma concentration available were divided into those that discontinued EFV because of any toxicity or by the choice of the patient or physician within 2 years (TOXPC group) and those that continued EFV for ≥2 years (no toxicity group). Multivariable logistic regression modelling was used to investigate the effects of the EFV plasma concentration and those of other potentially relevant factors on the risk of toxicity-induced EFV discontinuations.
Results
A total of 843 patients were included. Of these patients, 138 patients (16.4%) discontinued EFV because of TOXPC and 705 (83.6%) patients continued EFV for ≥2 years. A total of 20 (14.5%) patients in the TOXPC group had high EFV plasma concentrations (>4.0 mg/l) compared with 99 (14.0%) patients in the no toxicity group (P=0.890). A positive hepatitis C status (P=0.026), but not the EFV plasma concentration, was an independent predictor of toxicity-driven EFV discontinuations.
Conclusions
No association was found between EFV plasma concentrations and the risk of EFV discontinuations because of (CNS) toxicity. This result questions the designation of EFV plasma concentrations >4.0 mg/l as being ‘toxic’, at least when defined by treatment discontinuation.
References
1.
DHHS Panel.Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents, 3 November 2008. (Updated 3 November 2008. Accessed 1 August 2008.) Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
2.
GazzardB. on behalf of the BHIVA writing committee. BHIVA guidelines for the treatment of HIV-infected adults treated with antiretroviral therapy 2006. (Updated 10 June 2008. Accessed 1 August 2008.) Available from http://www.bhiva.org/files/file1001303.pdf.
3.
StaszewskiS., Morales-RamirezJ., TashimaK.T.Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.N Engl J Med1999; 341: 1865–1873.
BlanchJ., MartinezE., RousaudA.Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.J Acquir Immune Defic Syndr2001; 27: 336–343.
6.
GutierrezF., NavarroA., PadillaS.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Clin Infect Dis2005; 41: 1648–1653.
7.
MarzoliniC., TelentiA., DecosterdL.A., GreubG., BiollazJ., BuclinT.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.AIDS2001; 15: 71–75.
8.
NunezM., Gonzalez de RequenaD., GallegoL., Jimenez-NacherI., Gonzalez-LahozJ., SorianoV.Higher efavirenz plasma levels correlate with development of insomnia.J Acquir Immune Defic Syndr2001; 28: 399–400.
9.
GallegoL., BarreiroP., del RioR.Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz.Clin Infect Dis2004; 38: 430–432.
10.
La PorteC.J.L., BackD.J., BlaschkeT.Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.Reviews in Antiviral Therapy2006; 3: 4–14.
11.
KappelhoffB.S., van LethF., RobinsonP.A.Are adverse events of nevirapine and efavirenz related to plasma concentrations?Antivir Ther2005; 10: 489–498.
12.
StahleL., MobergL., SvenssonJ.O., SonnerborgA.Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects.Ther Drug Monit2004; 26: 267–270.
13.
RotgerM., ColomboS., FurrerH.Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.Pharmacogenet Genomics2005; 15: 1–5.
14.
TakahashiM., IbeS., KudakaY.No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.AIDS Res Hum Retroviruses2007; 23: 983–987.
15.
MocroftA., LedergerberB., KatlamaC.Decline in the AIDS and death rates in the EuroSIDA study: an observational study.Lancet2003; 362: 22–29.
AarnoutseR.E., GrintjesK.J., TelgtD.S.C.The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.Clin Pharmacol Ther2002; 71: 57–67.
18.
SulkowskiM.S., ThomasD.L., MehtaS.H., ChaissonR.E., MooreR.D.Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Hepatology2002; 35: 182–189.
19.
Martin-CarboneroL., NunezM., Gonzalez-LahozJ., SorianoV.Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.HIV Clin Trials2003; 4: 115–120.
NunezM.Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.J Hepatol2006; 44: S132–S139.
22.
PuotiM., TortiC., RipamontiD.Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.J Acquir Immune Defic Syndr2003; 32: 259–267.
23.
PereiraS.A., CaixasU., BrancoT.Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.Br J Clin Pharmacol2008; 66: 551–555.
24.
BarreiroP., Rodriguez-NovoaS., LabargaP.Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.J Infect Dis2007; 195: 973–979.
25.
HernandezB., MorenoS., Perez-EliasM.J.Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients.J Acquir Immune Defic Syndr2006; 43: 556–559.
26.
KappelhoffB.S., Van LethF., MacGregorT.R., LangeJ., BeijnenJ.H., HuitemaA.D.Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.Antivir Ther2005; 10: 145–155.
27.
KappelhoffB.S., HuitemaA.D., YalvacZ.Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.Clin Pharmacokinet2005; 44: 849–861.
28.
BurgerD., Van der HeidenI., la PorteC.Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.Br J Clin Pharmacol2006; 61: 148–154.
29.
PfisterM., LabbeL., HammerS.M.Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Antimicrob Agents Chemother2003; 47: 130–137.
30.
HaasD.W., RibaudoH.J., KimR.B.Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS2004; 18: 2391–2400.
31.
WardB.A., GorskiJ.C., JonesD.R., HallS.D., FlockhartD.A., DestaZ.The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.J Pharmacol Exp Ther2003; 306: 287–300.
32.
RotgerM., TegudeH., ColomboS.Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.Clin Pharmacol Ther2007; 81: 557–566.
33.
WyenC., HendraH., VogelM.Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.J Antimicrob Chemother2008; 61: 914–918.
34.
GatanagaH., HayashidaT., TsuchiyaK.Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.Clin Infect Dis2007; 45: 1230–1237.
35.
GulickR.M., RibaudoH.J., ShikumaC.M.Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.JAMA2006; 296: 769–781.
36.
CliffordD.B., EvansS., YangY.Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.Ann Intern Med2005; 143: 714–721.
